J.W. Cole Advisors Inc. Sells 592 Shares of Organon & Co. (NYSE:OGN)

J.W. Cole Advisors Inc. reduced its holdings in Organon & Co. (NYSE:OGN) by 4.5% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,440 shares of the company’s stock after selling 592 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Organon & Co. were worth $238,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Mercer Global Advisors Inc. ADV grew its holdings in shares of Organon & Co. by 1.8% during the second quarter. Mercer Global Advisors Inc. ADV now owns 31,086 shares of the company’s stock worth $674,000 after purchasing an additional 546 shares in the last quarter. Ballentine Partners LLC raised its position in shares of Organon & Co. by 3.0% during the 2nd quarter. Ballentine Partners LLC now owns 19,105 shares of the company’s stock valued at $395,000 after buying an additional 552 shares in the last quarter. Atomi Financial Group Inc. grew its position in Organon & Co. by 1.8% in the first quarter. Atomi Financial Group Inc. now owns 32,858 shares of the company’s stock worth $618,000 after acquiring an additional 593 shares in the last quarter. Bill Few Associates Inc. increased its stake in Organon & Co. by 5.4% in the second quarter. Bill Few Associates Inc. now owns 12,218 shares of the company’s stock valued at $253,000 after acquiring an additional 621 shares during the last quarter. Finally, GAMMA Investing LLC increased its stake in Organon & Co. by 19.2% in the second quarter. GAMMA Investing LLC now owns 4,036 shares of the company’s stock valued at $84,000 after acquiring an additional 649 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Down 3.7 %

Shares of NYSE OGN opened at $18.08 on Friday. The company has a market cap of $4.66 billion, a price-to-earnings ratio of 4.65, a PEG ratio of 0.81 and a beta of 0.84. Organon & Co. has a 52 week low of $10.84 and a 52 week high of $23.10. The company has a quick ratio of 1.17, a current ratio of 1.64 and a debt-to-equity ratio of 60.05. The firm’s fifty day moving average is $19.38 and its 200 day moving average is $20.10.

Organon & Co. (NYSE:OGN) last posted its earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.04. Organon & Co. had a net margin of 15.76% and a negative return on equity of 840.29%. The company had revenue of $1.61 billion during the quarter, compared to analyst estimates of $1.61 billion. During the same period in the prior year, the business posted $1.31 earnings per share. Organon & Co.’s revenue for the quarter was down .1% on a year-over-year basis. On average, equities research analysts expect that Organon & Co. will post 4.04 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th will be given a $0.28 dividend. The ex-dividend date is Tuesday, November 12th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.19%. Organon & Co.’s dividend payout ratio is currently 28.79%.

Analysts Set New Price Targets

Several equities analysts have recently commented on OGN shares. JPMorgan Chase & Co. lowered Organon & Co. from a “neutral” rating to an “underweight” rating and increased their price objective for the company from $18.00 to $20.00 in a research report on Friday, September 6th. Evercore ISI raised Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.